SARS-CoV-2 spike protein receptor-binding domain (Omicron BA.1 variant) (SARS-CoV-2 S-RBD (Omicron BA.1))

The SARS-CoV-2 spike protein receptor-binding domain (RBD) of the Omicron BA.1 variant is a key structural component of the SARS-CoV-2 virus, responsible for mediating entry into human host cells. It functions by binding with high affinity to the Angiotensin-Converting Enzyme 2 (ACE2) receptor on the surface of host cells, particularly in the respiratory tract (PubMed: 35016195). The Omicron BA.1 variant (B.1.1.529) is notable for harboring an unusually high number of mutations within the RBD, which enhance its binding affinity to ACE2 and contribute to its increased transmissibility (NIH: SARS-CoV-2 Variant Classifications). These mutations also allow the virus to evade many of the neutralizing antibodies elicited by previous infection or vaccination, as well as several clinical monoclonal antibody treatments (PubMed: 34954044). Consequently, the RBD is the primary target for the development of vaccines and therapeutic antibodies aimed at neutralizing the virus and preventing COVID-19 (UniProt: P0DTC2). Monitoring the evolution of the RBD is crucial for the ongoing adaptation of medical countermeasures against emerging SARS-CoV-2 variants.

Other names

SARS-CoV-2 S1-RBD (Omicron BA.1)Spike RBD (B.1.1.529)Omicron BA.1 RBDSARS-CoV-2 Spike RBD (B.1.1.529)

Monoclonal antibodies and vaccine-induced antibodies bind to the RBD, sterically hindering its interaction with the host ACE2 receptor, thereby preventing viral attachment and entry into host cells (PubMed: 35016195).